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I.

Introduction/Literature Review
According to the National Cancer Institute, breast cancer is the most commonly

occurring cancer in the United States. The estimated number of new cases of breast
cancer in 2019 was 268,600 with approximately 41,760 deaths.1 Although breast cancer
accounts for ~15.2% of all cancers, only 6.9% of cancer deaths are due to breast cancer.1
This low percentage of deaths relative to the number of cases is reflected in the five-year
survival rate from 2009-2015 of 89.9%.1 Although the survival percentage is high, it
varies with factors such as race/ethnicity and type of breast cancer.

Breast Cancer
Most breast cancers occur within the ducts of the breast. These ducts, which are
composed of epithelial cells, form the channels through which milk made within the
mammary gland travels to the nipple. Breast cancer can also occur within the lobes of the
gland. These two types of cancer are referred to as ductal or lobular carcinomas,
respectively2, and this represents one way in which breast cancer can be classified. Breast
cancer can also be classified into one of five molecular subtypes.3 The subtypes are based
on the presence or absence of estrogen and/or progesterone receptors and the expression
of Her2 (human epidermal growth factor receptor 2) (Table 1). Each receptor is key to
normal cellular proliferation and therefore, can serve as therapeutic targets for the
treatment of breast cancer.4 Luminal A and B subtypes are similar, but are distinguished
based on the levels of Ki67, which helps regulate the rate of cellular proliferation.
Luminal A cancers express low levels, whereas luminal B cancers express high levels of
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Ki67. The work in this thesis focuses on triple negative breast cancer (TNBC) cells,3
which lack estrogen and progesterone receptors, and Her2.

Subtype
Luminal A
Luminal B
TNBC
HER2
enriched
Normal-like

ER
+
+
-

PR
+
+
-

HER2
-/+
-

Ki67
+
++
-

+

+

+
-

-

Table 1: Receptor Expression in Breast Cancer Subtypes Expression of estrogen
receptor (ER), progesterone receptor (PR), and HER2 in each of the five different
molecular subtypes of breast cancer.3 (TNBC, triple negative breast cancer)

Triple Negative Breast Cancer
Of the five types of breast cancer, triple negative breast cancer is the most
aggressive. It accounts for 10% of all breast cancer diagnoses and has a 5-year survival
rate of 76.5%.5 In contrast, other subtypes have survival rates of 83.4-94%.5 Treatment
options for TNBC are fewer than those for other subtypes. With the expression of ER,
receptor antagonists can be used, and drugs such as Herceptin ® and lapatinib are available
to treat HER-2-positive cancers.6 These targeted therapies are not options for the
treatment of TNBC.
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Nuclear-Cytoplasmic Shuttling
The movement of certain proteins between the nucleus and cytoplasm of cells
allows their function to be localization dependent.7 Proteins less than 40 kDa can freely
diffuse through nuclear pores. Those with a molecular weight greater than 40 kDa are
shuttled in and out of the nucleus by specific carrier proteins, or karyopherins. Importins
are a type of karyopherin involved in the movement of protein and RNA from the
cytoplasm to the nucleus. These transporters recognize specific sequences within the
proteins termed nuclear localization sequences (NLS) that allow interaction and
translocation at the expense of Ran-GTP. Karyopherins involved in nuclear export of
proteins are referred to as exportins. There are many exportin proteins, but exportin 1
(XPO1, also known as chromosome region maintenance 1 or CRM1) binds to a leucine
rich nuclear export sequence (NES) within target proteins to move them out of the
nucleus and into the cytoplasm. This, too, requires energy generated by GTP hydrolysis
(Figure 1). 7
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Figure 1: Nuclear-cytoplasmic shuttling Before nuclear export can
occur, a complex of the exportin, cargo protein, and a Ran-GTP molecule
must be formed. Once the complex is exported to the cytosol, Ran-GTP is
hydrolyzed. This hydrolyzation provides energy for the exportin, cargo
protein, and Ran-GTP complex to dissociate from one another. The
exported protein remains in the cytosol and the exportin re-enters the
nucleus.
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The relevance of protein nuclear export to cancer is tied to the observations that a
number of proteins, including some that regulate the cell cycle, undergo nuclear import
and export as a means to regulate their function.8 Inhibition of nuclear export can result in
dysregulation of the cell cycle. For example, inhibition of nuclear export of cyclin D1, a
protein vital to cell cycle progression, results in tumor growth in immune compromised
mice.9 p53 is a protein that is activated in the nucleus when there is DNA damage or a
signal indicating the presence of oncogenic properties.7 Activated p53 stimulates
apoptosis and is exported once it has done its job. This export, and the export of many
other tumor suppressors, is carried out by XPO1, and many cancer cells overexpress
XPO1. In a non-cancerous cell, tumor suppressors are well-regulated by XPO1 to prevent
them from being activated in the nucleus when it is not necessary. When XPO1 is
overexpressed, it is constantly shuttling tumor suppressors out of the nucleus. This
promotes tumor formation and growth and can prevent apoptosis from occurring.7 The
ability to inhibit XPO1 activity could return the level of regulation in cancerous cells to
normal levels.

Selinexor, A Nuclear Export Inhibitor
Since XPO1 is upregulated in several types of cancer, it has become an attractive
therapeutic target, as pharmacological inhibition of nuclear export could serve to treat
patients. This concept has been proven effective in treating multiple myeloma, a cancer
of the bone marrow. Selinexor, a nuclear export inhibitor, received FDA approval for the
treatment of this cancer in 2019.10
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Selinexor is a first in class SINE (selective inhibitor of nuclear export) drug that
has been shown to induce apoptosis in triple negative breast cancer cells in vitro.11
Specifically, selinexor inhibits XPO1 by blocking its binding site for protein transport.
Studies indicate that selinexor treatment resulted in increased XPO1 mRNA expression,
suggesting that the cells were trying to compensate for reduced nuclear export by
synthesizing more XPO1.1
The successful outcomes from clinical trials resulted in an expedited approval
process for selinexor. Currently there are 21 ongoing clinical trials and nine trials have
been completed using the drug. For acute myeloid leukemia (AML), diffuse large B cell
lymphoma (DLBCL), multiple myeloma (MM), and soft tissue sarcoma, selinexor has
been given an orphan drug status in the United States. This means that a single
company has the rights to try to develop a cure for a certain disease while receiving
benefits such as tax reductions for certain clinical testing. In patients with breast cancer,
selinexor has been shown to have anticancer effects when combined with
chemotherapy.10
Selinexor is not the first nuclear export inhibitor designed. Leptomycin B was
first used in clinical trials in 1996.12 However, it was found to be too toxic to be used
therapeutically. Karyopharm Therapeutics has developed a series of compounds that are
structurally similar to leptomycin B. These compounds, designated with the prefix KPT,
were shown to inhibit nuclear export, with KPT-330 being the most efficacious. KPT-330
is selinexor.10
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PI3K/Akt
The PI3K/Akt pathway is frequently dysregulated in cancers and can contribute to
disease progression.13 Akt is a cell survival kinase. It has the ability to phosphorylate a
number of proteins to result in inhibition of apoptosis and changes in cell cycle
progression. Under normal conditions, Akt is activated when a growth factor binds to its
receptor, which has tyrosine kinase activity associated with it. Through adapter proteins,
phosphatidylinositol 3-kinase (PI3K) is activated and phosphorylates
phosphatidylinositol 4,5-biphosphate (PIP2) to produce phosphatidylinositol 3,4,5triphosphate (PIP3) on the plasma membrane. PIP3 recruits proteins that contain a
pleckstrin homology (PH) domain to the plasma membrane. This includes Akt and
pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1). PDK1 and Akt associate at
PIP3 on the membrane, and Akt is phosphorylated by PDK1 at threonine 308 (T308),
which partially activates Akt. Akt is further activated by phosphorylation by mTORC2
(mammalian target of rapamycin complex 2) at serine 473 (S473). Activated Akt
promotes cell growth, survival, and proliferation13 (Figure 2).
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Figure 2: Akt activation pathway Activation of PIP3 occurs when
growth factor binds to its tyrosine kinase receptor, initiating a cascade that
leads to the activation of Akt.

Akt function is regulated by phosphatase and tensin homolog (PTEN), which
regulates PIP3 by dephosphorylating it and returning it to PIP2. Loss of PTEN function
results in an increase in PIP3 and a constitutively activated Akt pathway. In addition,
studies have shown that when PTEN function is lost, breast cancer cells are more
sensitive to PI3K inhibitors.13
Akt function is also dependent upon the subcellular localization of the protein.
Akt translocates to the nucleus after being phosphorylated at the plasma membrane.14
Although the mechanism of Akt nuclear import is not fully understood15, Akt contains a
leucine-rich, leptomycin B sensitive, nuclear export sequence suggestive of nuclear
export occurring via XPO1.14
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While Akt s normal function aids in cellular survival, under certain conditions,
these functions can trigger apoptosis via reactive oxygen species (ROS) production. This
Akt-mediated increase in ROS has been demonstrated in glioblastoma and ovarian cancer
cell lines.16 These studies showed that the increase in ROS triggered cell death via
apoptosis.

Reactive Oxygen Species
Reactive oxygen species are oxygen radicals, such as hydroxyl radicals or
hydrogen peroxide (OH, H2O2), produced by normal cellular reactions. They are
important in many essential processes, such as immune defense mechanisms, but they can
also be volatile and toxic.17 While ROS are necessary, when their levels in the cell
become too high, oxidative stress occurs. This means that DNA, RNA, proteins, and
lipids, all essential molecules for cellular survival, can be damaged, which has
implications in overall health.19 ROS have both tumor suppressing and activating
properties, which some chemotherapies utilize to create toxicity to kill cancer cells.18
The PI3K/Akt pathway is frequently hyperactivated in cancer and this can result
in an increase in cellular ROS levels. This occurs via an increase in normal metabolic
processes that are activated by Akt and normally result in acceptable levels of ROS
production. However, many cancer cells already have higher level of ROS in comparison
to normal cells. Therefore, when more ROS are produced, the levels can become toxic
and trigger apoptosis.16
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Statement of Research Problem
Shuttling of proteins between the nucleus and cytoplasm can be an important
regulatory process in the development of cancer and therefore a key therapeutic target.
The nuclear export inhibitor selinexor, marketed as XPOVIO®, has been demonstrated to
be effective in the treatment of certain cancers. However, the full mechanism by which
this occurs is not known and very little is understood about its effects on triple negative
breast cancer. The working hypothesis of this thesis states that selinexor inhibits the
nuclear export of Akt, resulting in increased reactive oxygen species (ROS) and cell
death of TNBC cell lines.
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II.

Materials and Methods

BT-549 Cells
The primary focus of this research was to investigate the effects of selinexor in
triple negative breast cancer cells. Several triple negative breast cancer cell lines are
available for research purposes. For this project, BT-549 cells were used. BT-549 cells
are triple negative cells derived from a 72-year-old Caucasian female diagnosed with
ductal carcinoma.20 The cells have a homozygous deletion for PTEN, an inhibitor of the
PI3K/Akt pathway. Therefore, Akt should be constitutively active in these cells.

Cell Culture
BT-549 cells were purchased from American Type Culture Collection. They
were maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with
10% fetal bovine serum and 1% antibiotic-antimycotic solution. Cells were grown in a
humidified incubator at 37°C in 5% carbon dioxide.

Akt Activity Assays
Activity assays were performed using kits from Cell Signaling Technology or
Abcam. Cells were plated at a concentration of 5 x 106 cells in six 100 mm dishes.
Approximately 20 hours post plating, three plates were treated with 1 µM selinexor
(Selleck Chemical) and three were treated with corresponding volumes of dimethyl
sulfoxide (DMSO), the vehicle for selinexor, to serve as the negative control. The cells
were harvested 21 hours later by first rinsing them in cold phosphate-buffered saline
(PBS) followed by incubation in 0.5 mL cold Cell Lysis Buffer for 5 minutes. Cells were
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scraped off plates and transferred to microcentrifuge tubes to be sonicated on ice. The
cells were microcentrifuged for 10 minutes at 4ºC at 14,000 x g and the supernatant was
removed. This cell lysate, containing proteins, was stored at -80ºC, to be later used for
protein analysis.
The protein concentration for each sample was determined by BioRad Protein
Assay Dye Reagent Concentrate. Akt was immunoprecipitated from 200 µg of protein by
incubating overnight at 4ºC with immobilized phospho-Akt primary antibody conjugated
to beads. The immunoprecipitated Akt was isolated and incubated with glycogen
synthase kinase-3 (GSK-3) protein, for 30 minutes at 30ºC. GSK-3 is a known substrate
of Akt and its phosphorylation by the immunoprecipitated Akt indicates activation of the
kinase. The samples were then subjected to SDS-PAGE gel electrophoresis, and the
proteins were transferred to a membrane using the Trans-Blot Turbo Transfer System
(Bio-Rad). After blocking the membrane in blocking buffer (tris-buffered saline [TBST]
with 5% nonfat dried milk), it was incubated in a phospho-GSK 3 (Ser473) rabbit
monoclonal antibody at a 1:1000 dilution in 10mL blocking buffer overnight at 4ºC. The
following day, the membrane was rinsed three times for 10 minutes each before being
incubated with a horseradish peroxidase (HRP) conjugated donkey anti-rabbit IgG
secondary antibody (Jackson ImmunoResearch) at a 1:10,000 dilution in blocking buffer.
The membrane was rinsed again three times for ten minutes each and developed using the
SuperSignal West Pico PLUS Chemiluminescent Substrate Kit from Thermo Scientific.
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Western Blots
Cells were plated at a concentration of 5 x 106 cells in six 100 mm dishes.
Approximately 20 hours post plating, three plates were treated with 1 µM selinexor and
three were treated with DMSO, as a control. The cells were harvested 21 hours later by
first rinsing them in cold phosphate-buffered saline (PBS) followed by scraping in 1 mL
cold PBS per plate. The cells were collected into 15 mL conical tubes. The cells were
centrifuged at 500xg for 5 minutes at 4ºC, and the supernatant was decanted. Depending
on the size of the pellet, 35 µL- 50 µL of RIPA with Halt Phosphatase Inhibitor (Thermo
Scientific) and Protease Inhibitor Cocktail (Sigma) (final dilution of 1:100) was added
and the pellet resuspended before being transferred to a 1.5 mL microcentrifuge tube. The
tubes were vortexed for ~10 seconds before being placed on ice for 30 minutes. After the
30-minute period, DNA was sheared by using a 1mL syringe and a 24-gauge needle
before being centrifuged at 18,000 x g at 4ºC for 15 minutes. A protein assay using
BioRad Protein Assay Dye Reagent Concentrate was performed on the supernatant (cell
lysate) to determine protein concentration.
Western blots were performed to detect proteins by subjecting cell lysates to SDSPAGE gel electrophoresis, and the proteins were transferred to a membrane using the
Trans-Blot Turbo Transfer System (Bio-Rad). After blocking the membrane in blocking
buffer (tris-buffered saline [TBST] with 5% nonfat dried milk), it was incubated in a
primary antibody at a 1:1000 dilution in 10mL blocking buffer overnight at 4ºC. The
following day, it was washed three times for ten minutes each time before being
incubated with a secondary antibody at a 1:10,000 dilution in blocking buffer. The

14
membrane was washed again and developed using the SuperSignal West Pico PLUS
Chemiluminescent Substrate Kit from Thermo Scientific.
In order to ensure changes in Akt activity were not due to differences in Akt
protein levels, a total Akt Western blot was performed on both the vehicle (DMSO) and
selinexor-treated cell lysates. To probe for Akt, a pan antibody for Akt was used to
incubate the membrane. Western blots were also performed to analyze changes in the
levels of phosphorylated Akt as a second way of demonstrating Akt activity. This was
performed using a phospho (Thr308)-Akt rabbit polyclonal antibody to specifically
analyze Akt phosphorylation at threonine 308.
To ensure equal loading of the samples, the membranes from the total Akt and
phospho-Akt Westerns were stripped and reprobed for actin. The membranes were rewet
in methanol using the capillary technique. To strip the primary antibody from the
membrane, the membrane was washed six times in deionized water by shaking for 30
seconds each time before being incubated at room temperature in 0.1M HCl for 5 minutes
with shaking. Next, the membrane was incubated in blocking buffer on the shaker at
room temperature for 1 hour before being rinsed in 1x TBST. For actin reprobing of total
Akt Westerns, 3% BSA blocking buffer (0.3g bovine serum albumin, 10 mL 1x TBST)
was used, while for actin reprobing of phospho-Akt Westerns, 5% milk blocking buffer
(TBST with 5% dried milk) was used. The membrane was then incubated on the shaker
at room temperature for 30 minutes in a 1:1500 dilution of a monoclonal antibody against
ß-actin. The membranes were washed three times for 10 minutes each time before being
incubated for 45 minutes in the secondary antibody (peroxidase conjugated donkey antimouse IgG) at a 1:15,000 dilution in blocking buffer. After washing again, membranes
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were developed using the SuperSignal West Pico PLUS Chemiluminescent Substrate Kit
from Thermo Scientific. Equal signals between lanes demonstrated equal loading
between samples.

Indirect Immunofluorescence
To determine if selinexor caused nuclear accumulation of Akt, indirect
immunofluorescence was performed. BT-549 cells were plated at 750,000 cells per plate
on 35 mm MatTek dishes. After approximately 48 hours, cells were treated with 1 µM
selinexor or equal volume DMSO and harvested 21 hours later. Cells were washed in 1
mL filtered PBS and fixed in 2% paraformaldehyde. Cells were washed twice for five
minutes each in 1 mL 0.1M cold tris-glycine buffer. Cells were again washed with
filtered PBS for five minutes. Following incubation in blocking buffer (5% normal
donkey serum, 1% BSA, 0.1% Triton-X 100 in PBS) for 30 minutes, the primary Akt
(pan) antibody at a 1:400 dilution in blocking buffer was added. Plates were incubated
overnight at 4ºC in a moistened environment. The next day, the plates were washed three
times in filtered PBS for 5 minutes each. Cells were then incubated in a C

3 donkey

anti-rabbit IgG diluted at 1:1500 in blocking buffer in the dark at room temperature for
45 minutes. The cells were washed in filtered PBS three times for five minutes each.
Cells were then incubated in 4 ,6-diamidino-2-phenylindole (DAPI) at a 1:1500 dilution
in filtered PBS for two minutes. The cells were washed again in filtered PBS and then
rinsed in DI water before Aqua Poly Mount was added to the plate. Cells were viewed
under a Nikon Eclipse TI-5 fluorescence microscope. Cy3 was excited at 550 nm and
DAPI at 358 nm. Cells were imaged with NIS Elements BR4.6 imaging software.
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ROS Assays
To determine whether ROS were increased in response to selinexor, ROS assays
were performed. BT-549 cells were analyzed using the Cellular ROS Assay Kit (Red)
from Abcam. This procedure consisted of several steps. First, BT-549 cells were plated at
specified concentrations. The cells were then treated with 100 µL ROS Red Working
Solution and incubated at 37ºC for 1 hour. Next, the cells were treated with 20 µL of
selinexor at 1µM or 10 µM concentrations to induce ROS or corresponding volumes of
DMSO. One set of wells was treated only with 10 µL 1x PBS. Fluorescence changes
were monitored at 520 nm over varying time periods using the Bio-Tek Synergy 2
microplate reader and Gen 5 Microplate Data Collection and Analysis Software. If the
amount of ROS increased, the fluorescence intensity measured also increased.

Statistical Analysis
Data were quantified using LiCor Image Studio Lite software and analyzed using
GraphPad Prism Software. Data were evaluated using a two-tailed, paired student T-test.
Significance was set at less than 0.05.
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III.

Results

Selinexor Activates Akt
Akt is considered a cell survival kinase and it is generally thought that cell death
can result from decreases in its activity.21 To determine whether selinexor influenced Akt
activity levels in TNBC cells, Akt activity assays were performed to assess the levels of
active Akt in BT-549 cells treated with DMSO vehicle or with selinexor. Relative Akt
activity levels were determined by evaluating the phosphorylation of the Akt substrate
GSK-3 by performing Western blot analysis (Figure 3).
Under vehicle conditions, the levels of Akt activity were low to undetectable. In
contrast, the activity levels in cells treated with selinexor were higher than those in
vehicle-treated cells. In order to obtain a visible signal for the vehicle-treated samples,
the selinexor-treated samples band intensities were overe posed. Therefore, over the
course of the three independent experiments, the data were not quantifiable. However,
these results suggest that selinexor activates Akt in BT-549 cells.
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Figure 3: Akt Activity Western Blots Immunoprecipitated Akt was
incubated with GSK3, a substrate of Akt. Phosphorylated GSK3 is a
measure of Akt activity. The results show three independent experiments.

Selinexor Does Not Change Akt Protein Levels
To determine if Akt protein levels changed in response to selinexor, Western
blotting was performed on vehicle-treated and selinexor-treated cells (Figure 4). Probing
with a pan-Akt antibody (Figure 4A), the blot revealed no apparent difference in protein
levels between the two samples. In order to ensure equal protein loading onto the gel, the
membranes were stripped of primary antibody with 0.1 M HCl and reprobed for actin.
There appeared to be no difference in the actin levels between the two samples (Figure
4A). Densitometric analyses of bands revealed a slight increase in the Akt/actin ratio in
selinexor-treated cells; however, the increase was not statistically significant (p=0.353)
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(Figure 4B). Overall, these data imply that the selinexor-induced increases in Akt activity
were not due to elevated Akt protein levels but were reflections of increases in the
activity of the enzyme already expressed.
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Figure 4: Total Akt Western Blots 10 µg (Experiments 1 and 2) or 25 µg
(Experiment 3) of whole cell lysate was subjected to Western blot
analysis. (A) Blots were probed with a pan Akt antibody. The membranes
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were stripped and reprobed for actin. (B) Densitometric analysis of Akt
expression. P = 0.3531. Data shown are representative of three
independent experiments.

Selinexor Does Not Increase Akt T308 Phosphorylation
Initial activation of Akt occurs via phosphorylation at threonine 308, and for full
activation, phosphorylation of serine 473 follows. To corroborate the results of the Akt
activity assays, the levels of phospho-Akt were measured by Western blot using a
phospho-threonine308-specific Akt antibody (Figure 5). Probing with this phospho-Akt
antibody revealed that phosphorylation decreased or had no change upon treatment with
selinexor (Figure 5A). Densitometric analyses of bands revealed a slight decrease in the
phospho-Akt/actin ratio in selinexor-treated cells; however, the decrease was not
statistically significant (p=0.4671) (Figure 5B). Overall, these data imply that the increase
in Akt activity is not due to phosphorylation at threonine 308.
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Figure 5: Phospho-Akt Western Blots (A) Blots probed with phosphothreonine 308-specific Akt antibody. The membrane was stripped and
reprobed for actin. (B) Densitometric analysis of phosphorylated Akt at
threonine 308. P = 0.4671. Data shown are representative of 4 independent
experiments. Overflow of vehicle treated samples into lane 2 was
observed upon sample loading and was included in the quantification for
the vehicle sample.
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Selinexor Localizes Akt to the Nucleus
Since selinexor inhibits nuclear export and Akt localizes to the nucleus in some
cell lines14, the effects of selinexor on the subcellular localization of Akt in BT-549 cells
was evaluated. Indirect immunofluorescence was used to visualize the localization of Akt
in cells under vehicle or treatment conditions (Figure 6). If nuclear export of Akt had
been inhibited, the antibody would fluoresce red inside the nucleus more brightly in the
selinexor-treated cells when compared to vehicle-treated cells. Under vehicle conditions,
Akt was predominantly localized in the nucleus in a few cells and diffusely dispersed
throughout the cell in the majority of them. However, when treated with selinexor, Akt
predominantly localized to the nucleus. Based on overall observations, selinexor is able
to trap Akt in the nucleus by inhibiting XPO1 activity (Figure 6).
Cells within each field were counted and categorized as having approximately
equal staining intensity in the cytoplasm and nucleus or staining predominantly in
nucleus or cytoplasm (Table 2). In the vehicle treated cells, the majority (45%) of the
cells appeared to have Akt staining predominantly in the cytoplasm, with 35% of the cells
having diffuse staining throughout the cell. Of the cells treated with selinexor, 80%
appeared to have predominantly nuclear staining. These data suggest that selinexor
causes nuclear accumulation of Akt.
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Figure 6: Indirect Immunofluorescence of Akt in BT-549 Cells. Akt
was stained in red using a Cy3 antibody. Nuclei were stained in blue using
DAPI. Areas of overlap between the Akt protein (red) and the nucleus
(blue) appear as a purple color. Data shown are representative pictures of
2 independent experiments.
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Vehicle
(# of
cells)

Vehicle Selinexor
(%)
(# of cells)

Selienxor
(%)

Observation
Equal staining in cytoplasm and
nucleus
70
35%
14
Staining predominantly nuclear
29
15%
84
Staining predominantly cytoplasmic
89
45%
3
Staining too light to be detected
11
5%
4
Total Number
199
100%
105
Table 2: Localization of Intensity of Akt Staining in Vehicle and

13%
80%
3%
4%
100%

Selinexor Treated Cells Cells were counted and categorized by intensity
of Cy3TM staining and treatments.

ROS Assays
Hyperactivation of Akt has been demonstrated to evoke the production of ROS.21
The extent of activation of Akt in BT-549 cells treated with selinexor could be considered
hyperactivation. To determine if the cells produce ROS in response to treatment with
selinexor, ROS assays were performed. Four experiments were conducted using different
strategies. Cells were plated at three different densities and treated with 2 different
concentrations of selinexor. Fluorescence measurements were taken at different time
intervals.
In experiment one, cells were plated at concentrations of 30,000 cells per well
(Figure 7A) and 40,000 cells per well (Figure 7B). After one hour, absorbance
measurements observed for the cells plated at 30,000 cells per well were between 0.08
and 0.12. The well that received no treatment had a higher reading than three of the
remaining four treatments. After two hours, the readings were approximately 0.04, with
some slight differences between treatments. At 21 hours, the measurement again dropped
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slightly to be approximately 0.03. Twenty-four hours after treatment, two absorbance
values increased, while three decreased. One of these values became a negative value. In
the wells that contained 40,000 cells per well, the absorbance values after one hour were
between 0.05 and 0.1, with the cells that received no treatment being the next to highest
value. At 2 hours, all absorbance readings were below 0.05 and inconsistent, but the
10µM vehicle treatment value, which was the highest value at 1 hour, became negative.
At 21 hours, all values were positive again and around 0.03-0.04. After 24 hours, all
values were negative, with their absorbance values between -0.13-0.15.
In experiment two, cells were plated at 60,000 cells per well. At 19 hours and 21
hours, the highest absorbance values were for those cells that received no treatment. This
value stayed steady at a value of 0.025 throughout all three timepoints. At 3 hours, the
10µM selinexor treatment had the highest absorbance value. This value decreased
slightly at 19 hours and again at 21 hours, but it was still higher than the values for the
other treatments. In this experiment, the 1µM vehicle treatment yielded a higher
absorbance value than the 1µM selinexor treatment. However, the 1µM selinexor
treatment yielded higher absorbance values than the 10 µM vehicle treatment at 3 hours,
and these values were the same at both 19 and 21 hours.
The results from experiment three were also inconsistent. At 15 minutes, the
absorbance values for 1 µM vehicle and 10 µM selinexor were very low, while the values
for no treatment and 1 µM selinexor were between 0.2 and 0.3. After 30 minutes, the
absorbance reading for 1 µM selinexor treatment were extremely high, at a value of
around 0.45, while the other values were approximately 0.1 and lower. After an hour, the
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value for 1µM selinexor decreased slightly, while the values for no treatment and 1µM
vehicle treatment increased again.
Experiment four again shows inconsistent values. After 15 minutes, 1µM
selinexor treatment yielded a higher absorbance value than any other treatment, but at
both 30 minutes and 1 hour, 10 µM vehicle treatment yielded the highest absorbance
values. While most values decreased slightly over time, the 10µM vehicle treatment
values increased over time. In addition, the 10 µM selinexor treatment values never
exceeded 0.05 and remained relatively constant.
When analyzing this data, there were no consistent trends in absorbance values
when comparing between treatment options. Due to the negative and fluctuating
absorbance readings, over time, no reliable conclusion could be drawn from the data. In
spite of different experimental strategies, the data are insufficient to determine if
selinexor impacts ROS levels in BT-549 cells (Figure 7).
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ROS Assay- Experiment 1A

ROS Assay- Experiment 1B
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ROS Assay- Experiment 4
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Figure 7: ROS Assay Absorbance Readings Cells were treated in a 90well plate with 5 different treatments: no treatment, 1 µM DMSO, 1 µM
selinexor, 10 µM DMSO, and 10 µM selinexor. (A) Cells were plated at
30,000 cells per well. (B) Cells were plated at 40,000 cells per well. (A-B)
Absorbance readings were measured at 1 hour, 2 hours, 21 hours, and 24
hours. (C-E) Cells were plated at 60,000 cells per well. (C) Absorbance

10 µM S
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readings were measured at 3 hours, 19 hours, and 21 hours. (D-E)
Absorbance readings were measured at 15 minutes, 30 minutes, and 60
minutes. V, DMSO; S, Selinexor.
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IV.

Discussion/Conclusion
Selinexor is currently being used in several clinical trials for cancer and has

shown anti-cancer effects in combination with other chemotherapies. Clinical trials
evaluating the use of selinexor in the treatment of triple negative breast cancer are
limited, but in vitro studies show promising results in its ability to kill triple negative
breast cancer cells. The mechanism by which this occurs, however, is not understood.
The goal of this research was to determine the mechanism by which selinexor kills BT549 triple negative breast cancer cells.
Several key observations were made in this research. First, this work has
demonstrated that selinexor increases Akt activity. This was an unexpected finding. Since
Akt is generally associated with cell survival, the levels were expected to decrease. In
contrast, the levels were increased substantially. Hyperactivation of Akt has been
previously published by Wang et al. when they reported on the effects of targeting Akt
for potential therapy in diffuse large B-cell lymphoma.22 This hyperactivation may be the
mechanism utilized by selinexor in order to induce apoptosis in BT-549 cells.
Second, Akt phosphorylation is dependent on phosphorylation at T308. Therefore,
it was expected that selinexor would increase the phosphorylation of Akt at this site since
it induced Akt activity. The results did not indicate an increase in phosphorylation of
T308, which is required for full activation and downstream phosphorylation of Akt. This
is confounding as it is generally thought that this is the key to activation of the kinase.
However, other kinases, such as protein tyrosine kinase 6 (PTK6), have been shown to
activate Akt.13 PTK6 is not expressed in normal mammary tissue, but is expressed in
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many breast cancer cells. It phosphorylates Akt at tyrosines 315 and 326 and is localized
to the nucleus.23
Third, cells treated with selinexor show increased nuclear localization of Akt.
This indicates that inhibition of nuclear export in BT-549 cells results in nuclear retention
of Akt. One important function of nuclear Akt is inhibition of forkhead box protein O1
(FOXO) transcription factors, which results in decreased expression of FOXO proteins.
Since FOXO proteins are important for antioxidant production, decreased expression
could impact the ability of the cells to respond to oxidative stress, such as that caused by
hyperactivated Akt.
Lastly, the ROS assays gave inconclusive results, and need to be further
investigated. Previous experiments in the Odom lab have shown that selinexor kills BT549 cells by inducing apoptosis. An increase in ROS levels can cause oxidative stress and
ROS toxicity to trigger apoptosis. Apoptosis can be induced by many factors, but studies
have shown that cancer cells with constitutively activated Akt, such as BT-549 cells, are
more sensitive to ROS-induced apoptosis.16 Given this, it is still possible that levels of
ROS are affected. Figure 8 demonstrates a model schematic of these events.
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Figure 8: Proposed Method of Selinexor Induced BT-549 Cell Death
Selinexor inhibits the function of XPO1. Akt translocates to the nucleus
and/or mitochondria after being activated at the plasma membrane. In the
nucleus, Akt inhibits FOXO transcription factors and therefore decreases
the amount of FOXO and antioxidants produced. At the mitochondria, Akt
stimulates mitochondrial activity, resulting in an increase in the production
of ROS.

In conclusion, the data reported here suggests that Akt is being sequestered into
the nucleus and hyperactivated via an alternative mechanism of activation in BT-549
cells upon treatment with selinexor. Future experiments to investigate potential
alternative methods for Akt activation are needed. In addition, ROS assays would need to
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be repeated and cellular fractionation is needed to support the indirect
immunofluorescence observations.
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